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Abstract
There is scarce data about the importance of phylogroups and virulence factors (VF) in bloodstream infections (BSI) caused
by extended-spectrum b-lactamase-producing Escherichia coli (ESBLEC). A prospective multicenter Spanish cohort including
191 cases of BSI due to ESBLEC was studied. Phylogroups and 25 VF genes were investigated by PCR. ESBLEC were classified
into clusters according to their virulence profiles. The association of phylogropus, VF, and clusters with epidemiological
features were studied using multivariate analysis. Overall, 57.6%, 26.7%, and 15.7% of isolates belonged to A/B1, D and B2
phylogroups, respectively. By multivariate analysis (adjusted OR [95% CI]), virulence cluster C2 was independently
associated with urinary tract source (5.05 [0.96–25.48]); cluster C4 with sources other than urinary of biliary tract (2.89 [1.05–
7.93]), and cluster C5 with BSI in non-predisposed patients (2.80 [0.99–7.93]). Isolates producing CTX-M-9 group ESBLs and
from phylogroup D predominated among cluster C2 and C5, while CTX-M-1 group of ESBL and phylogroup B2
predominantes among C4 isolates. These results suggest that host factors and previous antimicrobial use were more
important than phylogroup or specific VF in the occurrence of BSI due to ESBLEC. However, some associations between
virulence clusters and some specific epidemiological features were found.
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Introduction
Most extraintestinal infections due to Escherichia coli are caused
by isolates derived from the so-called virulent phylogenetic groups
(PG) B2 and D, which exhibit more virulence factors (VF) than
other PGs such as A and B1, hence considered ‘‘low virulence’’ or
‘‘commensal’’ PGs [1,2]. Specifically, in studies on bloodstream
infections (BSI) caused by E. coli, .70% of the isolates belonged to
PGs B2 (which was predominant) and D [3–8]. Isolates from PG
B2 have been associated with BSI with a urinary tract source
[4,5,7] and in non-predisposed patients [7,9], while PG A has been
found with increased frequency in nosocomial BSI, compromised
hosts [4,6,10] and in BSI caused by antibiotic-resistant isolates
[5,6,8].
Some VFs have been assigned a pathogenic role in extraintes-
tinal infections based on comparisons with rectal isolates,
association with infections in non-predisposed patients, and animal
models [11]. In studies dealing with BSI, several VF has been
found to be associated with specific epidemiologic features, but it is
papGII that has been more consistently associated with urinary
tract sepsis as opposed to other sources, and in patients without
predisposing factors [4,9,12].
Extended-spectrum beta-lactamase-producing Escherichia coli
(ESBLEC) are increasing worldwide as a cause of community
and nosocomial BSI, frequently affecting patients with predispos-
ing conditions [12,13]. There are scarce data about the
distribution of PGs and VF in BSI due to ESBLEC [14] and
their association with antimicrobial resistance. Also, to the best of
our knowledge, the impact of specific VF in the epidemiology of
BSI due to ESBLEC has not been studied. Finally, there is some
controversy about the real virulence of ESBLEC, including isolates
producing CTX-M-15 belonging to the worldwide spread clone
ST131 [16–18].
The objectives of this study were to investigate the PGs and
prevalence of VF genes in a well characterized collection of
ESBLEC causing BSI, and whether some PGs and VF (individ-
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ually or in clusters) were associated with the epidemiology,
patients’ features and source of BSI.
Methods
Study Design and Patients
Data and isolates from a prospective cohort including 191 cases
of BSI due to ESBLEC from 13 Spanish hospitals were used for
this analysis. The epidemiology, clinical features, outcomes, types
of ESBL and susceptibility data of this cohort were previously
reported [13,14]. Briefly, all monomicrobial BSI in patients with
sign or symptoms of systemic infection caused by ESBLEC
diagnosed in the participating hospitals between October 2004
and January 2006 were included. The cases were detected by daily
review of microbiological results of blood cultures at each center.
Data collected included demographics, acquisition classified as
community, healthcare-associated or nosocomial [13], chronic
underlying diseases, severity of underlying condition according to
Charlson index [19], invasive procedures, exposure to antibiotics
in the preceding 2 months, and source of BSI according to clinical
and microbiological criteria.
For this analysis, patients with any of the following were
considered to have systemic predisposing features for BSI: diabetes
mellitus, liver cirrhosis, chronic renal insufficiency, inmunosup-
presive therapy, and neutropenia. Patients with a procedure-
associated BSI (including vascular catheter, urinary catheter,
endoscopic procedures and surgery), or any urinary or biliary tract
BSI in the presence of obstructive diseases of these tracts were
considered to have local predisposing factors for BSI. The study
was approved by the Ethics Committee of Hospital Universitario
Virgen Macarena which waived the need to obtained consent
because all data were analysed anonymously and the observational
nature of the study.
Microbiological Studies
Methods for bacterial identification, susceptibility studies and
ESBL confirmation and characterization were previously reported
[13,14]. Briefly, ESBL production and susceptibility by micro-
dilution to cefuroxime, cefotaxime, ceftazidime, cefepime, amox-
icillin-clavulanic acid, piperacillin-tazobactam, ciprofloxacin, gen-
tamycin, tobramycin, amikacin, ertapenem, imipenem, merope-
nem, trimethoprim-sulfamethoxazol, fosfomycin, and tigecycline
were studied according to CLSI recommendations [20]; a
resistance score (number of antimicrobials to which the isolate
was resistant) was calculated for each isolate. b-lactamase
characterization was carried out by isoelectric focusing, PCR of
the bla genes, and sequencing. ST131 clone was studied by O25b
typing [17] and analysis for allele 3 of pabB [21]; the phylogenetic
group was determined by multiplex PCR [22].
Twenty-five genes codifying for putative VF were studied,
including adhesins (papC, papGI, papGII, papGIII, fimH, sfaD/E,
afaB/C, iha); toxins (cnf1, cdtB, sat, hlyA); related to iron acquisition
(iucD, iroN, iutA, ireA, and fyuA); protectins (kps MTII, traT, cvaC, and
ompT); and miscellaneous (ibeA, maIX, svg, and usp). The presence/
absence of VF genes was studied by PCR using previously
described primers [2,23–31]. Total DNA was purified from each
strain with the UltraClean Microbial DNA purification kit (MO
BIO Laboratories Inc., Carlsbad, CA). DNAs were distributed in
96-well master plates and PCRs were done in 50 mL mixtures
containing 5 ml (20 ng) template DNA, 0.2 mM of each primer,
0.2 mM mix dNTPs and 1U DNA polymerase (Biotools S. L.,
Spain) in 1X buffer with MgCl2. PCR conditions were as follows:
5 min at 95uC, followed by 30 cycles of 30 s at 95uC, 30 s at
annealing temperature of each primer pair, 1 min at 72uC, and a
final 5 min incubation at 72uC. The PCR products were analyzed
by electrophoresis in 96-well agarose gels (VG-FAST, Fisher
Bioblock Scientific) stained with GelRedTM (Biotium Inc.). A
virulence score (number of VF genes) was calculated for each
isolate. The similarity of the isolates according to their VF
genotypes was studied by constructing a dendogram using the
binary patters (0, 1) of VF for each isolate; clusters of isolates were
identified using the Dice similarity coefficient. After reviewing the
data obtained, a 70% similarity threshold was used after reviewing
the data obtained (a 60% threshold was not discriminative enough,
since only one cluster included 72.2% isolates; and a 80%
threshold found only 4 clusters with .5 cases including 32.4% of
the isolates).
Statistical Analysis
Percentages were compared using the chi squared test or the
Fisher exact test, as appropriate, and continuous variables using
the Mann-Whitney U test. Multivariate analysis were performed
by logistic regression; variables with a univariate p value ,0.1
were introduced in the models, and selected using a stepwise
backward process; 0.1 was set as the limit for removal of terms. All
tests were performed using SPSS 18.0.
Results
Among the 191 ESBLEC bacteremic isolates, 55 (28.8%) belong
to PG A, 55 (28.8%) to PG B1, 51 (26.7%) belong to PG D, and 30
(15.7%) to B2. The median (IQR) virulence score were 10 (9–12)
for B2, 8 (7–9) for D, 5 (4–6) for B1, and 4 (2–6) for A. Among the
B2 isolates, 21 (70% of B2, 10.9% of the whole series) were O25b
and pabB3 positive and were considered as belonging to ST131.
For easier understanding, PGs A and B1 were analyzed together
because both showed similar virulence scores, frequency of VF
(only fimH, iucD, and iroN were significantly more frequent among
B1 than among A), ESBLs (predominance of CTX-M-14), and
resistance patterns.
The frequency of VF genes according to PG is shown in table 1.
In summary, papC, afaB/C, iha, fimH, sat, fyuA, iutA, kps MTII,
ompT, ibeA, usp, and maIX were more frequent among in B2 and D
than in A/B1; additionally, papGIII, hlyA, cnf1, and cdtB, although
infrequent, were more prevalent in B2 than in A/B1; and papGII
and ireA were more frequent in D than in A/B1. Finally, sfaD/E,
afaB/C, sat, fyuA, kps MTII, ompT, usp, and maIX were more
frequent in B2 than in D, while only papGII was more frequent in
D than in B2.
The distribution of the ESBL groups produced and resistance
profiles to antimicrobials according to PG are also shown in
table 1. ESBLs from the CTX-M-9 group (mainly CTX-M-14)
were the most frequent among D and A/B1 isolates, while those
from the CTX-M-1 group (mainly CTX-M-15) were the most
frequent among B2 isolates. As regards antimicrobial resistance,
isolates from the B2 PG showed a higher resistance score than A/
B1 and were more frequently resistant to amoxicillin-clavulanic
acid, tobramycin, and amikacin, while those from PG D were
more frequently resistant to co-trimoxazole and less to ceftazidime.
Among the B2 isolates, 21 (70%) were ST131. The ESBLs
produced by ST131 and non-ST131 B2 isolates differed; thus,
CTX-M-15 was produced by 15/21 of ST131 isolates (71.4%) and
by 0/9 of non-ST131 B2 isolates (p = 0.0007), while the numbers
for CTX-M-14 were 2/21 of ST131 and 5/9 of non-ST131 B2
isolates (9.5% vs. 55.5%, p = 0.01). In comparison with non-
ST131 B2 isolates, ST131 harboured more frequently afaA/B
(42.9% vs. 0, p = 0.02), iha (66.7% vs. 22.2%, p = 0.04), and sat
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Table 1. Virulence factor genes, ESBL groups and antimicrobial resistance of 191 ESBL-producing E. coli isolates causing BSI
according to phylogroups.
All isolates
(n = 191)
Phylogroup B2
(n = 30)
Phylogroup D
(n = 51)
Phylogroups A/B1
(n = 110)
Virulence score, median (IQR) 6 (4–8) 9 (8–13)a 7 (6–9) 6 (2–7)
VF
papC 45 (24) 8 (27) 23 (45)d 14 (13)
papGI 0 0 0 0
papGII 31 (16) 3 (10) 20 (39)c,d 8 (7)
papGIII 7 (4) 4 (13)a 1 (2) 2 (2)
sfaD/E 4 (2) 1 (3) 1 (2) 2 (2)
afaB/C 13 (7) 9 (30)a,b 4 (8)d 0
iha 30 (16) 16 (53)a,b 10 (20)d 4 (4)
fimH 160 (84) 28 (93)a 48 (94)d 84 (76)
hlyA 4 (2) 3 (10)a 1 (2) 0
cnf1 4 (2) 3 (10)a 1 (2) 0
cdtB 4 (2) 3 (10)a 1 (2) 0
sat 39 (20) 19 (63)a,b 17 (33)d 2 (3)
fyuA 98 (51) 28 (93)a,b 37 (73)d 33 (30)
iutA 157 (82) 28 (93)a 46 (90)d 83 (76)
iucD 140 (73) 23 (77) 41 (80) 76 (69)
iroN 118 (62) 17 (57) 29 (57) 72 (66)
kps MTII 44 (23) 20 (67)a,b 19 (37)d 5 (5)
traT 141 (74) 28 (83) 37 (72) 79 (72)
cvaC 66 (35) 7 (23) 16 (31) 43 (39)
ompT 102 (53) 27 (90)a,b 32 (63)d 43 (39)
ibeA 15 (8) 7 (23)a 7 (14)d 1 (1)
usp 33 (17) 26 (87)a,b 7 (14)d 3 (3)
maIX 75 (39) 28 (93)a,b 34 (67)d 13 (12)
svg 3 (2) 2 (7) 0 1 (1)
ireA 29 (15) 3 (10) 19 (37)c,d 7 (6)
ESBL groupf
CTX-M-9 groupg 122 (64) 10 (33) 41 (80)c,d 71 (65)
CTX-M-1 grouph 42 (22) 17 (57)a,b 8 (16) 17 (16)
SHV groupi 33 (17) 4 (13) 5 (10) 24 (22)
TEM group 1 (1) 0 0 1 (1)
Resistance to
Cefotaxime 184 (96) 28 (93) 50 (98) 106 (96)
Ceftazidime 70 (37) 14 (47)b 12 (24) 44 (40)e
Cefepime 124 (65) 19 (63) 35 (69) 70 (64)
Amoxicillin/clavulanic acid 73 (38) 19 (63)a,b 20 (39) 34 (31)
Piperacillin/tazobactam 16 (8) 5 (17) 3 (6) 8 (7)
Ciprofloxacin 129 (68) 18 (60) 36 (71) 75 (68)
Gentamycin 39 (20) 4 (13) 14 (28) 21 (19)
Tobramicin 34 (18) 13 (43)a,b 10 (20) 11 (10)
Amikacin 3 (2) 2 (7)a 1 (2) 0
Co-trimoxazole 115 (60) 19 (63) 38 (75)d 58 (53)
Resistance score, median (IQR) 5 (4–7) 6 (4–7)a 5 (4–6) 5 (4–5)
aHigher in B2 vs A/B1 (p,0.05).
bHigher in B2 vs D (p,0.05).
cHigher in D vs B2 (p,0.05).
dHigher in D vs A/B1 (p,0.05).
eHigher in A/B1 vs D (p,0.05).
All other comparisons, p.0.05.
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(81% vs. 22.2%, p = 0.004), and less frequently papGII (0 vs. 33.3,
p = 0.02) and ireA (0 vs. 33.3%, p = 0.02).
The features of the patients according to PG are shown in
table 2. Isolates from PG B2 and D did not seem to be related to
lower frequency of predisposing features for invasive infections
than isolates from PG A/B1. The only significant difference was
cancer, which was less frequent among patients with B2 isolates
than among those with A/B1. Also, there were not significant
differences in the epidemiological features or sources of BSI. Even
when B2 and D isolates were grouped, the only significant
difference with A/B1 isolates was that the former more frequently
occurred in nursing home residents (9/81 [11.1%] vs 3/110
[2.7%], p = 0.03).
The association of all 25 specific VF genes studied with
predisposing factors for BSI, type of acquisition, previous
antibiotic use, or source of BSI was studied. Overall, no association
was found (data not shown) with 2 exceptions: papGII was more
frequent in patients without any predisposing factor (local or
systemic) than in patients with them (25% vs 12%, p = 0.02), while
the opposite occurred with sat (25% vs 40%, p = 0.03). We also
performed stratified analysis according to source. Among patients
with a urinary tract source of BSI, those without any local or
systemic predisposing feature had isolates with a higher prevalence
of papC and papGII than those with any predisposing factor (46% vs
10%; p = 0.01, and 36% vs 7%; p = 0.001, respectively). No
significant associations were found between VF and other sources
of BSI.
The profiles of VF genes were extremely diverse: the 191 strains
showed 159 different profiles, of these 134 were unique, 21 profiles
appeared twice, 2 appeared three times, one profile was repeated
four times and another one appeared five times. Such diversity
prompted us to classify them in clusters; 29 clusters were found
using a 70% similarity threshold; 6 clusters arbitrarily named C1–
C6 grouped 128 isolates (67%). PGs, ESBLs, antimicrobial
resistance, and epidemiological data according to cluster are
shown in Table 3; distribution of VF among the clusters are shown
in Figure 1. In summary, isolates from C1 caused infections in
younger patients; those in C2 were associated with higher
frequency of urinary tract source; C4 isolates showed higher
frequency of CTX-M-1 group of ESBLs, resistance to amoxicillin/
clavulanic acid and tobramycin, and bacteremia from sources
other than urinary or biliary tracts; those in C5 had the lower
frequency of local predisposing factors; and C6 isolates showed less
frequent resistance for ciprofloxacin. Sixteen of the 22 isolates
from C4 (73%) belonged to ST131; also, 76% isolates from ST131
belonged to C4.
To further investigate the association of C2 with urinary tract
source, multivariate analysis were performed. We introduced the
following variables: age, gender, acquisition, local predisposing
factor, systemic predisposing factor, PG, cluster, papGII, VF score,
ESBLs, and antimicrobial resistance score. C2 was independently
associated with urinary tract source after controlling for age, local
and systemic predisposing factors, while PGs, papGII, VF score or
antimicrobial resistance were not (table 4). We did the same to
investigate the association of C4 with sources other than urinary or
biliary tracts. C4 was independently associated, while again PGs,
specific VF, VF score, and antimicrobial resistance score were not
(table 4).
Finally, we analyzed the association between different microbi-
ological features and absence of predisposing systemic and local
features for BSI. In the univariate analysis, cluster 5, papC, papGII,
sat, female gender, lower age, community, source, and no receipt
of previous antimicrobial use showed a p value ,0.1 and were
introduced in the multivariate analysis. The variables selected as
independent predictors of BSI in non-predisposed patients were
lower age, community-acquired BSI, no receipt of previous
antimicrobials, and cluster 5 (table 5).
Discussion
Our study showed that the phylogenetic background or
virulence profiles of ESBLEC causing BSI in Spain were different
to what would be expected for bacteremic E. coli. The fact that
isolates from the so-called ‘‘low virulent’’ PGs A and B1
predominated as caused of BSI is in contrast with previous studies
including mainly non-ESBL-producing isolates, in which B2 ad D
were predominant [3–8]. As a consequence, the prevalence of all
VF studied was much lower among ESBLEC isolates than among
previous collections of blood isolates of E. coli except for iutA, iroN,
traT, and cvaC [2–4,6,7,12]. There are, to our knowledge, scarce
previous data on collections of blood ESBLEC isolates. In a study
from The Netherlands including 41 ESBLEC blood isolates, only
22% of isolates belong to A or B1 PGs [15]. Similar to our results,
PG A was predominant in the subgroup of ESBL-producers from
a French study; however, only 19 ESBLEC were included [8].
Three facts may explain our results. First, most cases occurred
in patients with local or systemic predisposing factors for BSI;
hence, less virulence factors would be required to cause invasive
infection in such patients. Second, previous antibiotic treatment
was common, which would have selected for ESBLEC because of
their multidrug-resistant nature regardless their virulence profile.
Although antimicrobial resistance has been frequently shown to be
more frequent among isolates from the A and B1 PGs than among
B2 isolates [11], B2 isolates were more frequently resistant to
several antimicrobials (particularly amoxicillin-clavulanic acid and
tobramycin) than isolates from other PGs. This reflects the
resistance profile of isolates of ST131 producing CTX-M-15
[32,33], which comprised most B2 isolates in our series. And third,
in a recent study performed in France, non-ST131 B2 E. coli
isolates were found to rarely produce CTX-M enzymes [34]; this,
together with the fact that ST131 was not predominant in our
series, would provide an additional explanation for the low rate of
B2 isolates.
Even though ESBLEC from the B2 and D PGs showed, as
expected, a much higher content in VF, we did not find B2 and D
isolates to have caused infections in clearly less predisposed
patients than A/B1 isolates, with the exception of cancer (less
frequent among B2). A recent study on non-ESBL-producing E.
f7 isolates produced .1 ESBL.
gMainy CTX-M-14.
hMainly CTX-M-15.
iMainly SHV-12.
Data are presented as number of isolates (percentage) except where specified.
doi:10.1371/journal.pone.0044238.t001
Table 1. Cont.
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coli found that B2 isolates were predominant as cause of
bacteremia and spontaneous peritonitis in patients with liver
cirrhosis [35]; of note, liver cirrhosis was more frequent among
patient with B2 isolates than those with D or A/B1 isolates in our
series, but the differences did not reach statistical significance.
Also, we found that PGs or specific VFs were not independently
associated to source of BSI. In previous studies of E. coli
bacteremic isolates, those from PG B2 had been associated with
urinary tract source of BSI [4,5,7]. As regards specific VF, several
studies have investigated their association with BSI sources; the
studies were different in populations, definitions, and VF studied,
making it difficult to draw clear conclusions [4,9,12]. However,
papGII has been more consistently associated with urinary tract
source in these studies. We did not find such association, although
papGII was more frequent in crude analysis among non-
predisposed patients with urinary tract BSI.
Overall, these results suggest that host factors and previous
antimicrobial use were more important than phylogroup back-
ground, virulence score or specific VF in the occurrence of BSI
due to ESBLEC. However, by investigating the existence of
clusters of isolates according to their VF content, we found some
associations between virulence background and some specific
epidemiological features. Thus, cluster C2 (mainly PG D, CTX-
M-14 producers) was independently associated with urinary tract
Table 2. Comparison of predisposing features according to phylogroup among 191 patients with bacteremia due to ESBL-
producing E. coli.
All isolates
(n = 191)
Phylogroup B2
(n = 30)
Phylgroup D
(n = 51)
Phylogroups A/B1
(n = 110)
Age in years, median (IQR) 71 (55–78) 72 (58–82) 71 (58–78) 69 (54–77)
Male gender 107 (56) 20 (66.7) 28 (54.9) 59 (53.6)
Acquisition
Community 23 (12) 4 (13.3) 3 (5.9) 16 (14.5)
Healthcare-associated 72 (37.6) 12 (40) 24 (47.0) 36 (32.7)
Nosocomial 96 (50.2) 14 (46.7) 24 (47.9) 58 (52.7)
Nursing home resident 12 (6.2) 2 (6.7) 7 (13.7) 3 (2.7)
Charlson index, median (IQR) 2 (1–4) 2.5 (1–4) 2 (1–5) 2 (1–4)
Diabetes mellitus 52 (27.2) 9 (30) 12 (23.5) 31 (28.2)
Chronic pulmonary disease 34 (17.8) 4 (13.3) 9 (17.6) 21 (19.1)
Cancer 55 (28.7) 4 (13.3)a,b 15 (29.4) 36 (32.7)
Liver cirrhosis 18 (9.4) 5 (16.7) 4 (7.8) 9 (8.2)
Chronic renal insufficiency 28 (14.6) 3 (10) 5 (9.8) 20 (18.2)
Inmunosuppresive therapy 27 (14.1) 4 (13.3) 9 (17.6) 14 (12.7)
Obstructive urinary disease 43 (22.5) 7 (23.3) 7 (13.7)c 29 (26.4)
Biliary tract disease 18 (9.4) 2 (6.7) 3 (5.9) 13 (11.8)
Neutropenia 10 (5.2) 1 (3.3) 3 (5.9) 6 (5.5)
Urinary catheter 66 (34.5) 13 (43.3) 17 (33.3) 36 (32.7)
Central venous catheter 53 (27.7) 5 (16.7) 12 (23.5) 36 (32.7)
Mechanical ventilation 8 (4.1) 1 (3.3) 3 (5.9) 4 (3.6)
Previous surgery 44 (20.9) 6 (20) 14 (27.5) 24 (21.8)
Predisposing factor, local 122 (63.8) 19 (63.3) 30 (58.8) 73 (66.4)
Predisposing factor, systemic 100 (52.3) 16 (53.3) 24 (47.1) 60 (54.5)
Predisposing factors, systemic or local 158 (82.7) 24 (80) 41 (80.4) 93 (84.5)
Previous antibiotic use, any 107 (56) 18 (60) 28 (54.9) 61 (55.5)
Fluoroquinolones 49 (25.6) 7 (23.3) 12 (23.5) 30 (27.3)
Cephalospororins 53 (27.7) 9 (30) 15 (29.4) 29 (26.4)
Amoxicillin/clavulanic acid 20 (10.4) 3 (10) 3 (5.9) 14 (12.7)
Source
Urinary tract 90 (47.1) 12 (40) 25 (49) 53 (48.2)
Biliary tract 24 (12.5) 3 (10) 5 (9.8) 16 (14.5)
Othersd 77 (40.3) 15 (50) 21 (41.2) 41 (37.3)
aP value for B2 vs A/B1 = 0.03.
bP value for B2 vs D= 0.09.
cP value for D vs A/B1 = 0.07.
All other comparisons, P value $0.1.
dOther sources were: unkown, 25 patients; intraabdominal (non-biliar), 24; respiratory tract, 10; catheter-related, 9; miscellaneous, 8.
Data are expressed as number of cases (%) except where specified.
doi:10.1371/journal.pone.0044238.t002
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BSI; C4 (mostly B2 and ST131, CTX-M-15 producers) with non-
urinary or biliary tract sources; and C5 (mostly D and CTX-M-14
producers) with BSI in non-predisposed patients. All these clusters
had moderate to high virulence scores. The classification of isolates
into clusters according to VF had been previously carried out by
Johnson et al. according to clonal groups [36]; however, we
constructed the clusters by considering exclusively the VF content
of the isolates and without taking into account neither the
phylogroups nor any other clonal relationship among isolates
because our aim was to specifically investigate the influence of FV
Figure 1. Distribution of virulence factors according to clusters. Percentage of isolates: white: 0–25%; pale grey, 26–50%; dark grey, 51–75%;
black, .75%.
doi:10.1371/journal.pone.0044238.g001
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content by itself in the epidemiology of the infections. Hypothetical
implications from our data are that vaccines developed against
specific VFs might not be efficacious in avoiding invasive infections
due to ESBLEC in predisposed patients, and that reducing the
antibiotic pressure in such patients might be a more important
measure to try and reduce such infections in these patients.
Strengths of our study include its multicenter nature, clinical
data are comprehensive and were prospectively collected, and
isolates are well characterized. However, it has some limitations:
we could not compare the ESBLEC profiles with a control group
of non-ESBL producers and thus used collections from other
studies as a reference; we studied the genes codifying for VF, but
Table 3. Phylogroups, virulence score, ESBLs, selected antimicrobial resistance, and associated patients’ features of ESBL-
producing E. coli isolates causing BSI according to virulence profile clusters.
Cluster C1
(n = 55)
Cluster C2
(n = 11)
Cluster C3
(n = 8)
Cluster C4
(n = 22)
Cluster C5
(n = 25)
Cluster C6
(n = 7)
Other isolates
(n = 63)
Phylogroups
B2 0* 0* 25 90.9* 0* 57.1 6.3
D 10.9 54.4 75* 9.1 72* 42.9 15.9
A 23.6 18.2 0* 0* 16 0* 57.1
B1 65.5* 27.3 0* 0* 12 0* 20.6
Virulence score, median (IQR) 5 (5–6)* 8 (7–9)* 6 (6–7) 10 (10–12)* 8 (8–9)* 14 (12–15)* 4 (2–5)
ESBL groups
CTX-M-1 group 16.4 18.2 50 68.2* 8 28.6 12.7
CTX-M-9 group 70.9 72.7 62.5 27.3* 84 57.1 61.9
SHV group 16.4 9.1 0 4.5 16 14.3 27
Antimicrobial resistance
Ciprofloxacin 72.7 45.5 50 81.8 64 28.6* 69.8
Amoxicillin-clavulanic acid 29.1 45.5 37.5 68.2* 32 57.1 34.0
Tobramycin 7.3 18.2 12.5 54.5* 0* 14.3 22.2
Patients’ features
Age in years, median (IQR) 68 (50–76)* 73 (66–78) 76 (70–83) 72 (57–79) 71 (52–77) 80 (58–84) 70 (58–80)
Male gender 58.2 54.5 50 63.6 48 42.9 57.1
Community-onset 50.9 45.5 62.5 50 56 28.6 47.6
Nursing home resident 1.8 9.1 12.5 13.6 12 0 4.8
Median Charlson index (IQR) 2 (2–5) 2 (1–5) 2 (1–4) 2 (2–4) 3 (2–4) 3 (1–3) 2 (1–4)
Predisposing factor, local 72.7 72.7 75 59.1 44* 85.7 60.3
Predisposing factor, systemic 60 37.3 50 50 40 71.4 54
Urinary tract source 52.7 81.8* 37.5 40.9 48 28.6 41.3
Biliary tract source 7.3 0 25 0 12 28.6 20.6
Other sources 40 18.2 37.5 59.1* 40 42.9 38.1
*P values ,0.05 in comparison with isolates not included in the cluster.
Data are presented as percentage of isolates in each cluster except where specified.
doi:10.1371/journal.pone.0044238.t003
Table 4. Multivariate analysis of variables associated with
specific sources of bloodstream infection.
OR (95% CI) P
Urinary tract source
Age (per year) 1.02 (1.00–1.04) 0.009
Local predisposing factor 2.10 (1.11–3.98) 0.002
Systemic predisposing factor 0.57 (0.31–1.04) 0.07
Cluster C2 5.05 (0.96–26.48) 0.05
Non urinary or biliary tract sources
Age (per year) 0.96 (0.94–0.98) 0.001
Local predisposing factor 0.27 (0.14–0.54) ,0.001
Systemic predisposing factor 2.75 (1.41–5.36) 0.003
Cluster C4 2.89 (1.05–7.93) 0.03
doi:10.1371/journal.pone.0044238.t004
Table 5. Multivariate analysis of variables associated with
absence of local or systemic predisposing conditions.
OR (95% CI) P
Absence of systemic and local predisposing factors
Age (per year) 0.97 (0.94–1.00) 0.04
Community-onset BSI 2.62 (1.02–6.76) 0.04
No previous antibiotics 5.69 (2.24–14.45) ,0.001
Cluster 5 2.80 (0.99–7.93) 0.05
doi:10.1371/journal.pone.0044238.t005
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this does not necessarily reflect the expression of these VF during
infection; and results might not be applicable to areas with a
different epidemiology of ESBLEC.
In conclusion, bacteremic ESBLEC more frequently belonged
to PGs A and B1 and thus had a lower virulent content than
expected; neither PGs or specific VF were consistently associated
with predisposing features or sources of BSI; and some clusters of
isolates identified according to their virulence profile were
identified and associated with specific source or acquisition of
BSI in the absence of predisposing factors.
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